ACLS D	DRUG OVERVIEW	Leadership and Excellence in Healthcare Education
EPINEPHRINE	(VASOPRESSOR) Indicated in cardiac arrest. Inc and peripheral vascular resistance. Standard Arr E-T Tube: 2.0-3.0 mg diluted in 10cc NS. Also fo hypotension as a Drip: 2-10 mcg/minutes.	creases heart rate, increase contractility rest Dose: 1 mg IV q3-5 min (1:10,000). or profound bradycardia and/or
VASOPRESSIN	(VASOPRESSOR) May be used in the Pulseless an epinephrine. May give 1 dose – 40u IV/IO to rep	rrest as an alternative pressor to lace first or second dose of epinephrine.
AMIODARONE	(ANTIARRHYTHMIC) Used for both atrial and ve shock-refractory VT/VF Arrest Dose: 300 mg IVP, 3-5min. Tachycardia Dose: 150 mg over 10 min. Bradycardia Hypotension. **Useful in controlling rate of atrial fibrillation and	ntricular arrhythmias. Indicated for consider repeating with 150 mg IVP in Max 2.2 gm/24 hr. Side effects are atrial flutter with WPW.
PROCAINAMIDE	(ANTIARRRHYTHMIC) Used in a wide variety of mg/min. End points: Maxinum dose of 17 mg/kg (50%, hypotension, control of arrhythmia. Note: widening and prolong QT intervals. Drip: 1 Gm/2 <i>**Useful in controlling rate of atrial fibrillation (with</i>	f arrhythmias. Non-arrest dose: 20-50 (1.2 Gm for 70 kg patient), or QRS widens may cause torsades de pointes with QRS 50cc's at 1-4 mg/min. th rapid pulse) in WPW.
SOTALOL NEW	(ANTIARRHYTHMIC) Treatment of supraventricul without structural heart disease. Should be avoid because of significant negative inotropic effects. hypotension, and torsades de pointes. IV dose: insert recommends slow infusion, but literature su over 5 minutes or less.	lar and ventricular arrhythmias in patients led in patients with poor perfusion Adverse effects include bradycardia, 1-1.5 mg/kg over 5 minutes. Package upports a more rapid infusion of 1.5mg/kg
LIDOCANE	(ANTIARRHYTHMIC) Used for ventricular arrhyth VT/Vfib Dose: 1.0 – 1.5 mg/kg IV total-3.0 mg/l Drip: 1Gm/250cc at 1-4mg/min.	nmias. An alternative to Amiodarone for kg. E-T Tube: 2.0 – 4.0 mg/kg.
MAGNESIUM SULFATE	Indicated in cardiac arrest – Torsades de Pointes pulse and life threatening arrhythmias due to dig 50% solution) diluted. IVP in full arrest. 1-2g in non-arrest.	Indicated for torsades de pointes with a italis toxicity. Dose: 1-2 Gm (2-4 ml of a 50 to 100 ml of DSW over 5-60 minutes in
ADENOCARD	Short half-life (<10 seconds). Slows A-V node co narrow complex PSVT. Does not convert atrial fib IV push, followed by 20ml NS push, may repeat precautions/contraindications in ECC Handbook.	nduction. First drug for most forms of rillation, flutter or MAT. Dose: 6mg rapid twice after 1-2 min at 12mg IVP. See
ATROPINE	Decreases vagal reflex, accelerates the rate of si the nodal level. Bradycardia dose: 0.5mg IVP q3	inus node, may be useful in AV Block at 3-5 minutes – total 0.04mg/kg.
DOPAMINE	Inotropic & Chronotropic: 1-4mcg/kg/min – (low 11-20mcg/kg/min = (vasopressor dose). Useful hypotension, symptomatic bradyarrhythmias. C/ requirements or worsen ischemia. Drip: 400mg i	dose); 5-10mcg/kg/min = (cardiac dose) in the treatment of cardiogenic shock, AUTION: May increase myocardial oxygen in 250cc = 1600mcg/cc
NITROGLYCERIN	Sublingual or IV drip. Vasodilator. Useful in the rel angina or ACS, antihypertensive, CHF.	ief of chest pain in angina/unstable

# **MORPHINE** Rellief of pain in ACS: small, frequent doses (2-4mg) IV. Titrate to pain or hemodynamics. May be useful in pulmonary edema.

- **BETA BLOCKER** Indicated for rate control and hypertension in ACS patients. Also used in the treatment of high-risk unstable angina and SVTs without impaired pumping function. Shown to reduce the incidence of Vfib. Examples: metoprolol, atenolo, propanolo, esmolol & labetalol.
- **SODIUM BICARB** Not recommended for routine use in cardiac arrest patients. Adequate ventilation and CPR, not bicarbonate, are the major "buffer agents" in cardiac arrest. May be responsive acidosis, prolonged arrest, and certain drug overdoses. Dose: 1mEg/kg IV.

# **CALCIUM** Verapamil & Diltiazem are calcium channel blocking agents that slow conduction and increase refractoriness in the AV node. Used to terminate reentry SVTs and to control rate in patients with Afib, Aflutter, or MAT.

**ACE INHIBITORS** Used to reduce mortality in post AMI patients by limiting infarct expansion. They block an enzyme in the body that is necessary to produce a substance that causes blood vessels to tighten. As a result, they relax blood vessels. This lowers blood pressure and increases the supply of blood and oxygen to the heart. Examples: Elanapril, Captopril, Lisinopril, Rampril.

#### **GLYCOPROTEIN IIb/IIIa INHIBITORS** These agents thin blood by blocking platelets. They effectively reduce the risk for heart attack or death in patients with unstable angina and non-Q-wave infarctions when used in combination with heparin or aspirin. Examples: Reopro, Integrilin, Aggrastat.

#### **FIBRINOLYTIC THERAPY** Clot busting drugs used for AME and Acute Ischemic Stroke. AMI Thrombolytic Package includes aspirin, heparin and a thrombolytic agent, e.g., Alteplase (TPA), Streptokinase, APSAC, Retavase, Tenecteplase (TNK).

# For AMI in Adults:

ST elevation (1mm or more in at least two contiguous leads) or new or presumably new LBBB; strongly suspicious for injury

>In context of signs and symptoms of AMI

>Time from onset of symptomes <12 hours

# For Acute Ischemic Stroke:

(Alteplase is the only thrombolytic agent approved for acute ischemic stroke)

 Sudden onset of focal neurological deficits or alterations in consciousness (e.g., facial droop, arem drift, abnormal speech)
Absence of intracerebral or subarachnoid hemorrhage or mass effect on CT scan
Absence of variable or rapidly improving neurological deficits
Alteplase can be started in <3 hours from symptom onset</li>

### **ETT - Instillation**: (Drugs that can be given via the Endotracheal Tube)

-LEAN-L idocaine E pinephrine A tropine N arcan (must be diluted)

-NAVEL-N arcan (must be diluted) A tropine E pinephrine V asopressin L idocaine